Oncotarget

Research Papers:

Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside

Julien Fleurence, Denis Cochonneau, Sophie Fougeray, Lisa Oliver, Fanny Geraldo, Mickaël Terme, Mylène Dorvillius, Delphine Loussouarn, François Vallette, François Paris and Stéphane Birklé _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:41172-41185. https://doi.org/10.18632/oncotarget.9226

Metrics: PDF 1238 views  |   HTML 1649 views  |   ?  


Abstract

Julien Fleurence1,2,*, Denis Cochonneau3,*, Sophie Fougeray1,2,4, Lisa Oliver1,2,5, Fanny Geraldo1,2, Mickaël Terme3, Mylène Dorvillius3, Delphine Loussouarn1,2,5, François Vallette1,2,6, François Paris1,2,5,6, Stéphane Birklé1,2,4

1INSERM U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, France

2CNRS 6299, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, France

3OGD2 Pharma, Institut de Recherche en Santé de l’Université de Nantes, Nantes, France

4Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France

5Centre Hospitalier Universitaire de Nantes, Nantes, France

6LaBCT, Institut de Cancérologie de l’Ouest-René Gauducheau, Saint-Herblain, France

*These authors contributed equally to this work

Correspondence to:

Stéphane Birklé, email: Stephane.Birkle@univ-nantes.fr

Keywords: glioblastoma, ganglioside, immunotherapy

Received: September 29, 2015     Accepted: April 22, 2016     Published: May 09, 2016

ABSTRACT

There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylat GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9226